Cargando…

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographica...

Descripción completa

Detalles Bibliográficos
Autores principales: Advani, Shailesh Mahesh, Advani, Pragati Shailesh, Brown, Derek W., DeSantis, Stacia M., Korphaisarn, Krittiya, VonVille, Helena M., Bressler, Jan, Lopez, David S., Davis, Jennifer S., Daniel, Carrie R., Sarshekeh, Amir Mehrvarz, Braithwaite, Dejana, Swartz, Michael D., Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796359/
https://www.ncbi.nlm.nih.gov/pubmed/31623592
http://dx.doi.org/10.1186/s12885-019-6144-9
_version_ 1783459568011968512
author Advani, Shailesh Mahesh
Advani, Pragati Shailesh
Brown, Derek W.
DeSantis, Stacia M.
Korphaisarn, Krittiya
VonVille, Helena M.
Bressler, Jan
Lopez, David S.
Davis, Jennifer S.
Daniel, Carrie R.
Sarshekeh, Amir Mehrvarz
Braithwaite, Dejana
Swartz, Michael D.
Kopetz, Scott
author_facet Advani, Shailesh Mahesh
Advani, Pragati Shailesh
Brown, Derek W.
DeSantis, Stacia M.
Korphaisarn, Krittiya
VonVille, Helena M.
Bressler, Jan
Lopez, David S.
Davis, Jennifer S.
Daniel, Carrie R.
Sarshekeh, Amir Mehrvarz
Braithwaite, Dejana
Swartz, Michael D.
Kopetz, Scott
author_sort Advani, Shailesh Mahesh
collection PubMed
description BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21–24%; I(2) = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.
format Online
Article
Text
id pubmed-6796359
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67963592019-10-21 Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer Advani, Shailesh Mahesh Advani, Pragati Shailesh Brown, Derek W. DeSantis, Stacia M. Korphaisarn, Krittiya VonVille, Helena M. Bressler, Jan Lopez, David S. Davis, Jennifer S. Daniel, Carrie R. Sarshekeh, Amir Mehrvarz Braithwaite, Dejana Swartz, Michael D. Kopetz, Scott BMC Cancer Research Article BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21–24%; I(2) = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions. BioMed Central 2019-10-17 /pmc/articles/PMC6796359/ /pubmed/31623592 http://dx.doi.org/10.1186/s12885-019-6144-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Advani, Shailesh Mahesh
Advani, Pragati Shailesh
Brown, Derek W.
DeSantis, Stacia M.
Korphaisarn, Krittiya
VonVille, Helena M.
Bressler, Jan
Lopez, David S.
Davis, Jennifer S.
Daniel, Carrie R.
Sarshekeh, Amir Mehrvarz
Braithwaite, Dejana
Swartz, Michael D.
Kopetz, Scott
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title_full Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title_fullStr Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title_full_unstemmed Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title_short Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
title_sort global differences in the prevalence of the cpg island methylator phenotype of colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796359/
https://www.ncbi.nlm.nih.gov/pubmed/31623592
http://dx.doi.org/10.1186/s12885-019-6144-9
work_keys_str_mv AT advanishaileshmahesh globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT advanipragatishailesh globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT brownderekw globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT desantisstaciam globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT korphaisarnkrittiya globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT vonvillehelenam globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT bresslerjan globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT lopezdavids globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT davisjennifers globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT danielcarrier globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT sarshekehamirmehrvarz globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT braithwaitedejana globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT swartzmichaeld globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer
AT kopetzscott globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer